Related Experiment Videos
Treatment of Pediatric Cholestatic Liver Disease
Valeria C. Cohran1, James E. Heubi
1Division of Pediatric Gastroenterology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA. james.heubi@cchmc.org
Insights
Effective management of cholestatic liver disease in children focuses on nutrition and portal hypertension complications. This approach aims to improve quality of life and survival, potentially reducing the need for liver transplantation.
Area of Science:
- Pediatric Hepatology
- Gastroenterology
- Internal Medicine
Background:
- Cholestatic liver diseases affect a small percentage of children but incur significant healthcare costs.
- Complications such as portal hypertension, nutritional deficiencies, and pruritus impact patient quality of life and survival.
- Co-existing conditions like cardiac or renal disease influence the overall prognosis.
Purpose of the Study:
- To highlight the importance of comprehensive medical management for pediatric cholestatic liver diseases.
- To emphasize strategies for improving patient outcomes and reducing the need for liver transplantation.
- To discuss the management of complications associated with portal hypertension.
Main Methods:
- Review of current therapeutic approaches for pediatric cholestatic liver diseases.
- Analysis of the impact of nutritional status and portal hypertension on patient prognosis.
- Discussion of evolving treatment modalities, including endoscopic therapies versus surgical shunts.
Main Results:
- Close monitoring of nutritional status and portal hypertension sequelae can enhance patient quality of life and survival.
- Endoscopic therapies (sclerotherapy, band ligation) are increasingly preferred over surgical shunts.
- Despite medical advancements, conditions like biliary atresia and PFIC may still necessitate liver transplantation.
Conclusions:
- Meticulous medical management of nutrition and portal hypertension complications is crucial for prolonging survival in pediatric cholestatic liver disease.
- Optimizing non-transplant management may reduce morbidity and mortality associated with liver transplantation.
- Integrated care plans addressing comorbid conditions are essential for improving patient prognosis.
Abstract:
Cholestatic liver disease affects a small percentage of children, but therapy results in millions of healthcare dollars being spent each year. Close monitoring of nutritional status, pruritus, and complications from portal hypertension should improve the patient's quality of life and survival without liver transplantation. Other comorbid conditions, such as cardiac or renal disease, must also be integrated into the care plan and will affect the overall prognosis of the patient. Portal hypertension leads to ascites, variceal hemorrhage, and infection, which can result in significant mortality if not promptly recognized and treated. Surgical shunts are being used less because the expertise to perform endoscopic sclerotherapy and endoscopic band ligation is available at most medical centers. However, many cholestatic diseases, including biliary atresia, progressive familial intrahepatic cholestasis (PFIC) I, II, and III, and Alagille syndrome, may still require liver transplantation (Table 1). The cost of this procedure can exceed several hundred thousand dollars per patient, without including the annual costs of immunosuppressant therapy and medical monitoring. Meticulous medical management of nutrition and the sequelae of portal hypertension may prolong survival and reduce the potential morbidity and mortality of liver transplantation.